Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 67

1.

A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - A twelve month follow-up.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

J Neuroimmunol. 2015 Aug 15;285:68-70. doi: 10.1016/j.jneuroim.2015.05.019. Epub 2015 May 20.

PMID:
26198921
2.

B Cells and Autoantibodies in Multiple Sclerosis.

Pröbstel AK, Sanderson NS, Derfuss T.

Int J Mol Sci. 2015 Jul 21;16(7):16576-92. doi: 10.3390/ijms160716576. Review.

3.

Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis.

Derfuss T, Bergvall NK, Sfikas N, Tomic DL.

Curr Med Res Opin. 2015 Jun 29:1-16. [Epub ahead of print]

PMID:
26121423
4.

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS.

Kappos L, Radue EW, Comi G, Montalban X, Butzkueven H, Wiendl H, Giovannoni G, Hartung HP, Derfuss T, Naegelin Y, Sprenger T, Mueller-Lenke N, Griffiths S, von Rosenstiel P, Gottschalk R, Zhang Y, Dahlke F, Tomic D; TOFINGO study group.

Neurology. 2015 Jul 7;85(1):29-39. doi: 10.1212/WNL.0000000000001706. Epub 2015 May 29.

5.

Anti-MOG antibodies are present in a subgroup of patients with a neuromyelitis optica phenotype.

Pröbstel AK, Rudolf G, Dornmair K, Collongues N, Chanson JB, Sanderson NS, Lindberg RL, Kappos L, de Seze J, Derfuss T.

J Neuroinflammation. 2015 Mar 8;12:46. doi: 10.1186/s12974-015-0256-1.

6.

A pragmatic approach to dealing with fingolimod-related lymphopaenia in Europe.

Giovannoni G, de Jong B, Derfuss T, Izquierdo G, Mazibrada G, Molyneux P, Nicholas R, Overell J, Ziemssen T, Juliusson G.

Mult Scler Relat Disord. 2015 Jan;4(1):83-4. doi: 10.1016/j.msard.2014.09.215. Epub 2014 Oct 13. No abstract available.

PMID:
25787058
7.

Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Costa GD, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeño JC, Kleinová P, Horáková D, Roesler R, Lauda F, Llufriu S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmestrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibali V, Romano S, Martínez AD, Carra A, Salvetti M, Uccelli A, Torkildsen Ø, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg R, Yaldizli Ö, Vécsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdová E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintoré M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G.

Mult Scler. 2015 Jul;21(8):1013-24. doi: 10.1177/1352458514568827. Epub 2015 Feb 13.

PMID:
25680984
8.

Interferon beta and vitamin D synergize to induce immunoregulatory receptors on peripheral blood monocytes of multiple sclerosis patients.

Waschbisch A, Sanderson N, Krumbholz M, Vlad G, Theil D, Schwab S, Mäurer M, Derfuss T.

PLoS One. 2014 Dec 31;9(12):e115488. doi: 10.1371/journal.pone.0115488. eCollection 2014.

9.

A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.

Derfuss T, Curtin F, Guebelin C, Bridel C, Rasenack M, Matthey A, Du Pasquier R, Schluep M, Desmeules J, Lang AB, Perron H, Faucard R, Porchet H, Hartung HP, Kappos L, Lalive PH.

Mult Scler. 2015 Jun;21(7):885-93. doi: 10.1177/1352458514554052. Epub 2014 Nov 12.

PMID:
25392325
10.

Unraveling natalizumab effects on deregulated miR-17 expression in CD4+ T cells of patients with relapsing-remitting multiple sclerosis.

Meira M, Sievers C, Hoffmann F, Rasenack M, Kuhle J, Derfuss T, Kappos L, Lindberg RL.

J Immunol Res. 2014;2014:897249. doi: 10.1155/2014/897249. Epub 2014 May 12.

11.

MiR-126: a novel route for natalizumab action?

Meira M, Sievers C, Hoffmann F, Derfuss T, Kuhle J, Kappos L, Lindberg RL.

Mult Scler. 2014 Sep;20(10):1363-70. doi: 10.1177/1352458514524998. Epub 2014 Mar 5.

PMID:
24598267
12.

Cerebellar abnormalities contribute to disability including cognitive impairment in multiple sclerosis.

Weier K, Penner IK, Magon S, Amann M, Naegelin Y, Andelova M, Derfuss T, Stippich C, Radue EW, Kappos L, Sprenger T.

PLoS One. 2014 Jan 22;9(1):e86916. doi: 10.1371/journal.pone.0086916. eCollection 2014.

13.

Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis.

Kuhle J, Malmeström C, Axelsson M, Plattner K, Yaldizli O, Derfuss T, Giovannoni G, Kappos L, Lycke J.

Acta Neurol Scand. 2013 Dec;128(6):e33-6. doi: 10.1111/ane.12151. Epub 2013 Jun 13.

PMID:
23763388
14.

Aquaporin-4 antibody negative recurrent isolated optic neuritis: clinical evidence for disease heterogeneity.

Waschbisch A, Atiya M, Schaub C, Derfuss T, Schwab S, Lee DH, Müller M, Linker RA.

J Neurol Sci. 2013 Aug 15;331(1-2):72-5. doi: 10.1016/j.jns.2013.05.012. Epub 2013 Jun 2.

PMID:
23735776
15.

Natalizumab therapy for multiple sclerosis.

Derfuss T, Kuhle J, Lindberg R, Kappos L.

Semin Neurol. 2013 Feb;33(1):26-36. doi: 10.1055/s-0033-1343793. Epub 2013 May 25. Review.

PMID:
23709210
16.

T-cell response against varicella-zoster virus in fingolimod-treated MS patients.

Ricklin ME, Lorscheider J, Waschbisch A, Paroz C, Mehta SK, Pierson DL, Kuhle J, Fischer-Barnicol B, Sprenger T, Lindberg RL, Kappos L, Derfuss T.

Neurology. 2013 Jul 9;81(2):174-81. doi: 10.1212/WNL.0b013e31829a3311. Epub 2013 May 22.

PMID:
23700335
17.

Recommendations for the use of prolonged-release fampridine in patients with multiple sclerosis (MS).

Preiningerova JL, Baumhackl U, Csepany T, Czaplinski A, Deisenhammer F, Derfuss T, Fabjan TH, Fazekas F, Fuchs S, Havrdova E, Ledinek AH, Illes Z, Jazbec SS, Klimova E, Komoly S, Kurca E, Linnebank M, Lisy L, Mares J, Prochazkova L, Csilla R, Szilasiova J, Stourac P, Talab R, Turcani P, Vachova M, Vecsei L, Vodusek D, Zapletalova O, Berger T.

CNS Neurosci Ther. 2013 May;19(5):302-6. doi: 10.1111/cns.12101.

PMID:
23607697
18.

Predicting PML in natalizumab-treated patients: can we do better?

Derfuss T, Kappos L.

J Neurol Neurosurg Psychiatry. 2013 Nov;84(11):1182-3. doi: 10.1136/jnnp-2012-304777. Epub 2013 Apr 20. No abstract available.

PMID:
23606737
19.

[What's new in multiple sclerosis therapy?].

Vaney C, Derfuss T.

Rev Med Suisse. 2013 Jan 30;9(371):285-7. German. No abstract available.

PMID:
23451607
20.

Neurofascin as a target for autoantibodies in peripheral neuropathies.

Ng JK, Malotka J, Kawakami N, Derfuss T, Khademi M, Olsson T, Linington C, Odaka M, Tackenberg B, Prüss H, Schwab JM, Harms L, Harms H, Sommer C, Rasband MN, Eshed-Eisenbach Y, Peles E, Hohlfeld R, Yuki N, Dornmair K, Meinl E.

Neurology. 2012 Dec 4;79(23):2241-8. doi: 10.1212/WNL.0b013e31827689ad. Epub 2012 Oct 24.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk